Last reviewed · How we verify
Epanova (OMEGA-3-CARBOXYLIC ACIDS)
At a glance
| Generic name | OMEGA-3-CARBOXYLIC ACIDS |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Omega-3 Fatty Acid |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Hypertriglyceridemia
Common side effects
Key clinical trials
- Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis (PHASE3)
- Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (PHASE3)
- Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery. (NA)
- Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
- Immunonutrition for Diabetic Foot Ulcers (PHASE2,PHASE3)
- The Effect of Omega-3 Fatty Acids Versus Gabapentin in Uremic Pruritus in Hemodialysis Patients (NA)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE3)
- Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19 (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epanova CI brief — competitive landscape report
- Epanova updates RSS · CI watch RSS
- AstraZeneca portfolio CI